OptiNose (Germany) Top Insiders
0OP Stock | EUR 0.38 0.01 2.70% |
OptiNose employs about 189 people. The company is managed by 22 executives with a total tenure of roughly 129 years, averaging almost 5.0 years of service per executive, having 8.59 employees per reported executive. Examination of OptiNose's management performance can provide insight into the company performance.
Peter Miller CEO Chief Executive Officer, Director |
Ramy Mahmoud President President, Chief Operating Officer |
OptiNose |
OptiNose Management Team Effectiveness
The company has return on total asset (ROA) of (0.312) % which means that it has lost $0.312 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (10.505) %, meaning that it generated substantial loss on money invested by shareholders. OptiNose's management efficiency ratios could be used to measure how well OptiNose manages its routine affairs as well as how well it operates its assets and liabilities.OptiNose Workforce Comparison
OptiNose is number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is presently estimated at about 62,829. OptiNose adds roughly 189 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of (0.97) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.76) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.76. OptiNose Notable Stakeholders
An OptiNose stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as OptiNose often face trade-offs trying to please all of them. OptiNose's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting OptiNose's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Peter Miller | Chief Executive Officer, Director | Profile | |
Ramy Mahmoud | President, Chief Operating Officer | Profile | |
Keith Goldan | Chief Financial Officer | Profile | |
Sandra Helton | Independent Director | Profile | |
Tomas Heyman | Director | Profile | |
Anthony Krick | VP Officer | Profile | |
John Messina | Sr Affairs | Profile | |
Catherine Owen | Director | Profile | |
Jonathan Neely | VP Operations | Profile | |
Joshua Tamaroff | Independent Director | Profile | |
Joseph Scodari | Independent Chairman of the Board | Profile | |
Sriram Venkataraman | Independent Director | Profile | |
Wilhelmus Groenhuysen | Independent Director | Profile | |
Michele MBA | VP CFO | Profile | |
Robert ONeil | Independent Director | Profile | |
Karen Brophy | Chief HR | Profile | |
William Doyle | Independent Director | Profile | |
Michael Esq | Chief Sec | Profile | |
Victor Clavelli | Chief Commercial Officer | Profile | |
Per MD | CoFounder AS | Profile | |
Michael Marino | Chief Legal Officer and Corporate Secretary | Profile | |
MPH MD | Pres COO | Profile |
About OptiNose Management Performance
The success or failure of an entity such as OptiNose often depends on how effective the management is. OptiNose management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of OptiNose management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the OptiNose management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania. OPTINOSE INC operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 204 people.
OptiNose Workforce Analysis
Traditionally, organizations such as OptiNose use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare OptiNose within its industry.OptiNose Manpower Efficiency
Return on OptiNose Manpower
Revenue Per Employee | 395K | |
Revenue Per Executive | 3.4M | |
Net Loss Per Employee | 435.4K | |
Net Loss Per Executive | 3.7M |
Complementary Tools for OptiNose Stock analysis
When running OptiNose's price analysis, check to measure OptiNose's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OptiNose is operating at the current time. Most of OptiNose's value examination focuses on studying past and present price action to predict the probability of OptiNose's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OptiNose's price. Additionally, you may evaluate how the addition of OptiNose to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Stocks Directory Find actively traded stocks across global markets | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |